Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABSK021 |
Synonyms | |
Therapy Description |
ABSK021 selectively inhibits CSF1R, potentially leading to inhibition of tumor cell proliferation, enhanced T cell immune response, and antitumor activity (NCI Drug Dictionary, J Clin Oncol 41, 2023 (suppl 16; abstr 11559). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABSK021 | ABSK 021|ABSK-021|CSF-1R Inhibitor ABSK021|Pimicotinib | CSF1R Inhibitor 28 | ABSK021 selectively inhibits CSF1R, potentially leading to inhibition of tumor cell proliferation, enhanced T cell immune response, and antitumor activity (NCI Drug Dictionary, J Clin Oncol 41, 2023 (suppl 16; abstr 11559). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05804045 | Phase III | ABSK021 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor | Active, not recruiting | USA | POL | NLD | ITA | ESP | CAN | 1 |
NCT04192344 | Phase I | ABSK021 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK021 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |